Several proof of principle study assays have been carried out to explore the capacity of FAPα as a local pro-drug activator of engineered cytotoxic pro-drugs for cancer treatment, including the combination with photoactivation in peptide-locked photosensitizers [12,13,14]. This evidence concerns the gene FAP and cancer.